Emerging drugs and combination strategies for basal cell carcinoma

Bibliography

• Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166(5):1069-80
   PubMed Web of Science ®Google Scholar
• Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353(21):2262-9
   PubMed Web of Science ®Google Scholar
• Bulliard JL, Panizzon RG, Levi F. Epidemiology of epithelial skin cancers. Rev Med Suisse 2009;5(200):882-884-8
   PubMedGoogle Scholar
• Dreier J, Felderer L, Barysch M, et al. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opin Pharmacother 2013;14(10):1307-18
   PubMed Web of Science ®Google Scholar
• Walling H, Fosko S, Geraminejad P, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004;23(3-4):389-402
   PubMed Web of Science ®Google Scholar
• Trakatelli M, Morton CA, Nagore E, et al. Update of the Guideline on Basal Cell Carcinoma [WWW document] URL. 2012. Available from: http://www.euroderm.org/images/stories/guidelines/guideline_Basal_Cell_Carcinoma-update2012%20.pdf
   Google Scholar
• Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine 1987;66(2):98-113
   PubMed Web of Science ®Google Scholar
• Archer TC, Weeraratne SD, Pomeroy SL. Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol 2012;30(17):2154-6
   PubMed Web of Science ®Google Scholar
• McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014;50(4):774-83
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146(Suppl 61):1-6
   PubMed Web of Science ®Google Scholar
• European_Skin_Cancer_Foundation. Basal cell carcinoma. Available from: http://www.escf-network.eu/en/patients/skin-cancer/basal-cell-carcinoma.html [Cited 15 January 2014]
   Google Scholar
• American_Cancer_Society. Cancer Facts & Figures 2013. Atlanta; 2013. Available from: www.cancer.gov
   Google Scholar
• Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003;327(7418):794-8
   PubMed Web of Science ®Google Scholar
• Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30(5 Pt 1):774-8
   PubMed Web of Science ®Google Scholar
• Roche_Pharma_AG. Dossier zur Nutzenbewertung gemaß § 35a SGB V; Vismodegib (Erivedge®); Modul 3 A; 2013 31.07.2013
   Google Scholar
• Dreier J, Bogdan AI, Cheng P, Dummer R. Basal cell carcinomas in a tertiary referral centre- a systematic analysis [abstract] (Poster). World melanoma congress EADO Meeting; 17 – 20 July 2013; Hamburg, Germany
   Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;17;361(12):1173-8
   PubMed Web of Science ®Google Scholar
• Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg 2011;30(Suppl 4):S14-18
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366(23):2171-9
   PubMed Web of Science ®Google Scholar
• Hutchin ME, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev 2005;19(2):214-23
   PubMed Web of Science ®Google Scholar
• Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003;3(12):903-11
   PubMed Web of Science ®Google Scholar
• Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 2002;16(21):2743-8
   PubMed Web of Science ®Google Scholar
• Binns W, James LF, Shupe JL, Everett G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum Californicum. Am J Vet Res 1963;24:1164-75
   PubMed Web of Science ®Google Scholar
• Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8(10):743-54
   PubMed Web of Science ®Google Scholar
• Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 2004;14(2):96-102
   PubMed Web of Science ®Google Scholar
• Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19(19):5576-81
   PubMed Web of Science ®Google Scholar
• Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455(7211):406-10
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding. Clin Cancer Res 2011;17(8):2512-20
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361(12):1164-72
   PubMed Web of Science ®Google Scholar
• Graham RA, Hop CE, Borin MT, et al. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 2012;74(5):788-96
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month erivance BCC Study Update. ESMO; 28 September – 2 October 2012; Vienna
   Google Scholar
• Sekulic A MM, Oro A, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): 18-month ERIVANCE BCC study update. J Clin Oncol 2013;31(Suppl):abstract 9037
   Google Scholar
• Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366(23):2180-8
   PubMed Web of Science ®Google Scholar
• Grob JJ, Kunstfeld R, Dréno B, et al.et al. Vismodegib, a Hedgehog pathway inhibitor, in advanced basal cell carcinoma: STEVIE Study interim analysis in 300 patients. ASCO meeting; 31 May – 4 June 2013; Chicago
   Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A phase 1, multicenter, open-label, first-in-human, dose-escalation study of the oral Hedgehog inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014;20(7):1900-9
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov Identifier: NCT01327053
   Google Scholar
• Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011;131(8):1735-44
   PubMed Web of Science ®Google Scholar
• Peukert S, He F, Dai M, et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem 2013;8(8):1261-5
   PubMed Web of Science ®Google Scholar
• Siu LL, Papadopoulos K, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol 2010;28(Suppl):abstract 2501
   Google Scholar
• Bendell J, Weiss G, Infante J, et al. 594 A phase I dose-escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) evaluation of LY2940680, an oral Smo inhibitor. Eur J Cancer 2012;48(6):182
   Google Scholar
• Goldman JW, Eckhardt SG, Borad M, et al. Phase 1 dose-escalation trial of the investigational Hedgehog (HH) pathway inhibitor TAK-441 in patients with advanced solid tumors [abstract 2739]. ESMO congress; 2012
   Google Scholar
• Teperino R, Amann S, Bayer M, et al. Hedgehog Partial Agonism Drives Warburg-like Metabolism in Muscle and Brown Fat. Cell 2012;151(2):414-26
   PubMed Web of Science ®Google Scholar
• Straface G, Aprahamian T, Flex A, et al. Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med 2009;13(8b):2424-35
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326(5952):572-4
   PubMed Web of Science ®Google Scholar
• Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res 2011;71(15):5057-61
   PubMed Web of Science ®Google Scholar
• Litwack G. Hedgehog signaling. Preface. Vitam Horm 2012;88:xxi-xxii
   PubMedGoogle Scholar
• Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2(51):51ra70
   PubMed Web of Science ®Google Scholar
• Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71(2):435-44
   PubMed Web of Science ®Google Scholar
• Riobo NA, Lu K, Ai X, et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA 2006;Mar;21;103(12):4505-10
   PubMed Web of Science ®Google Scholar
• Hafner C, Landthaler M, Vogt T. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Exp Dermatol 2010;19(8):e222-e7
   PubMed Web of Science ®Google Scholar
• Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10(3):143-53
   PubMed Web of Science ®Google Scholar
• Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013;10(4):191-210
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov Identifier: NCT01576666. Available from: www.clinicaltrials.gov
   Google Scholar
• Mimeault M, Johansson SL, Vankatraman G, et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007;6(3):967-78
   PubMed Web of Science ®Google Scholar
• Schnidar H, Eberl M, Klingler S, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009;69(4):1284-92
   PubMed Web of Science ®Google Scholar
• Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012;4(3):218-33
   PubMed Web of Science ®Google Scholar
• Palmer SR, Erlichman C, Fernandez-Zapico M, et al. Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. J Clin Oncol 2011;29(Suppl):abstract 3092
   Google Scholar
• Krähn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001;37(2):251-9
   PubMed Web of Science ®Google Scholar
• Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008;39(3):344-9
   PubMed Web of Science ®Google Scholar
• Lewis CM, Glisson BS, Feng L, et al. A phase II study of Gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18(5):1435-46
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Loven J, Xu N, et al. MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Oncogenesis 2012;1:e3
   PubMed Web of Science ®Google Scholar
• Sand M, Skrygan M, Sand D, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res 2013;351(1):85-98
   PubMed Web of Science ®Google Scholar
• Heffelfinger C, Ouyang Z, Engberg A, et al. Correlation of global microRNA expression with basal cell carcinoma subtype. G3 (Bethesda) 2012;2(2):279-86
   PubMedGoogle Scholar
• Bigelow RLH, Chari NS, Undén AB, et al. Transcriptional regulation of bcl-2 mediated by the sonic Hedgehog signaling pathway through gli-1. J Biol Chem 2004;279(2):1197-205
   PubMed Web of Science ®Google Scholar
• Delehedde M, Cho SH, Sarkiss M, et al. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer 1999;85(7):1514-22
   PubMed Web of Science ®Google Scholar
• Rodriguez-Villanueva J, Colome MI, Brisbay S, McDonnell TJ. The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers. Pathol Res Pract 1995;191(5):391-8
   PubMed Web of Science ®Google Scholar
• Smoller BR, Van De Rijn M, Lebrun D, Warnke RA. BCL-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol 1994;131(1):28-31
   PubMed Web of Science ®Google Scholar
• Regl G, Kasper M, Schnidar H, et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res 2004;64(21):7724-31
   PubMed Web of Science ®Google Scholar
• Chen X-l, Cheng Q-y, She M-r, et al. Expression of sonic Hedgehog signaling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro. Arch Med Res 2010;41(5):315-23
   PubMed Web of Science ®Google Scholar
• Matthews J. Bcl-2 Inhibitors. In: Roberts GK, editor. Encyclopedia of biophysics. Springer; Berlin Heidelberg: 2013. p. 184
   Google Scholar
• Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27(Suppl 1):S149-57
   PubMedGoogle Scholar
• Oakes SR, Vaillant F, Lim E, et al. Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci 2012;109(8):2766-71
   PubMed Web of Science ®Google Scholar
• van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10(5):389-99
   PubMed Web of Science ®Google Scholar
• Mason KD, Khaw SL, Rayeroux KC, et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009;23(11):2034-41
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;2;435(7042):677-81
   PubMed Web of Science ®Google Scholar
• Kunkalla K, Liu Y, Qu C, et al. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol 2013;92(6):777-87
   PubMed Web of Science ®Google Scholar
• Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol 2006;16(5):543-7
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7(7a):1126-32
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu S, Sun W, et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 2013;56(13):5553-61
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol 2010;3(1):1-12
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53(12):2736-9
   PubMed Web of Science ®Google Scholar
• Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55(1):96-107
   PubMed Web of Science ®Google Scholar
• Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;Jan;1;59(1):1-7
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88(3):323-31
   PubMed Web of Science ®Google Scholar
• Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10(12):1321-8
   PubMed Web of Science ®Google Scholar
• Grinkevich VV, Nikulenkov F, Shi Y, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009;15(5):441-53
   PubMed Web of Science ®Google Scholar
• Krajewski M, Ozdowy P, D'Silva L, et al. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 2005;11(11):1135-6; author reply 6-7
   PubMed Web of Science ®Google Scholar
• NCI Drug Dictionary: p53/HDM2 interaction inhibitor CGM097. Available from: www.cancer.gov/drugdictionary
   Google Scholar
• Clinical Trials.gov Identifier: NCT01760525. Available from: www.clinicaltrials.gov
   Google Scholar
• Kim J, Tang JY, Gong R, et al. Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth. Cancer Cell 2010;17(4):388-99
   PubMed Web of Science ®Google Scholar
• Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014;32:(8):745-51
   PubMed Web of Science ®Google Scholar
• Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci 2010;107(30):13432-7
   PubMed Web of Science ®Google Scholar
• Xia J, Li Y, Yang Q, et al. Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci 2012;13(8):9627-41
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov Identifier: NCT01791894
   Google Scholar
• Kim J, Aftab Blake T, Tang Jean Y, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013;23(1):23-34
   PubMed Web of Science ®Google Scholar
• Karagas MR, Stukel TA, Morris JS, et al. Skin cancer risk in relation to Toenail arsenic concentrations in a US population-based Case-Control Study. Am J Epidemiol 2001;153(6):559-65
   PubMed Web of Science ®Google Scholar
• Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer. Cancer 2002;94(2):477-85
   PubMed Web of Science ®Google Scholar
• Kim KH, Yavel RM, Gross VL, Brody N. Intralesional interferon α-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004;30(1):116-20
   PubMed Web of Science ®Google Scholar
• Buechner SA. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 1991;24(5 Pt 1):731-4
   PubMed Web of Science ®Google Scholar
• Buechner S, Wernli M, Bachmann F, et al. Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer Res 2002;160:246-50
   PubMedGoogle Scholar
• Li C, Chi S, He N, et al. IFN[alpha] induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 2003;23(8):1608-17
   Web of Science ®Google Scholar
• Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139(10):1325-32
   PubMed Web of Science ®Google Scholar
• Wolff F, Loipetzberger A, Gruber W, et al. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene 2013;32(50):5574-81
   PubMed Web of Science ®Google Scholar
• Makinodan E, Marneros AG. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin. Exp Dermatol 2012;21(11):847-52
   PubMed Web of Science ®Google Scholar
• Walter A, Barysch MJ, Behnke S, et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res 2010;16(14):3562-70
   PubMed Web of Science ®Google Scholar